Judith Shizuru

BMT specialist, Hematologist

Associate Professor of Medicine (Blood and Marrow Transplantation)

Blood and Marrow Transplant Program

  • 875 Blake Wilbur Drive
  • Palo Alto, CA 94304
  • Phone: 650-723-0822
Learn More About the Clinic Getting Here Make An Appointment

Hematology Program

  • 875 Blake Wilbur Drive
  • Palo Alto, CA 94304
  • Phone: 650-498-6000
Learn More About the Clinic Getting Here Make An Appointment

Professional Education

Internship: UCSF Medical Center (1993) CA

Residency: UCSF Medical Center (1994) CA

Fellowship: Stanford University Medical Center (1997) CA

Medical Education: Stanford University School of Medicine (1992) CA

Honors & Awards

Scholar Award, Amy Strelzer Manasevit (2001)

Junior Faculty Scholars Award, Howard Hughes Medical Institute (1996-2000)

Career Award in the Biomedical Sciences, Burroughs Wellcome Fund (1996-2000)

Excellence in Research in the Field of Hematopoiesis, Cheryl Whitlock Award (1996)

Postdoctoral Fellowship, Juvenile Diabetes Foundation (1991-1993)

Postdoctoral Fellowship, Juvenile Diabetes Foundation (1989-1991)

Postdoctoral Fellowship, Juvenile Diabetes Foundation (1986-1988)

Clinical Trials

Clinical trials are research studies that evaluate a new medical approach, device, drug, or other treatment. As a Stanford Health Care patient, you have access to the latest, advanced clinical trials.

Open trials refer to studies currently accepting participants. Closed trials are not currently enrolling, but may open in the future.

Total Lymphoid Irradiation-Antithymocyte Globulin Conditioning and Allogeneic Transplantation for Patients with Myelodysplastic Syndromes and Myeloproliferative Neoplasms
Benjamin, J., Chhabra, S., Kohrt, H. E., Lavori, P., Laport, G. G., & Lowsky, R. (2014). Total Lymphoid Irradiation-Antithymocyte Globulin Conditioning and Allogeneic Transplantation for Patients with Myelodysplastic Syndromes and Myeloproliferative Neoplasms. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 20(6), 837-843.

Donor hematopoiesis in mice following total lymphoid irradiation requires host T-regulatory cells for durable engraftment
Mueller, A. Ms., Poyser, J., Upper, N. Jk., Burnett, C., Ko, R. M., & Shizuru, J. A. (2014). Donor hematopoiesis in mice following total lymphoid irradiation requires host T-regulatory cells for durable engraftment. BLOOD, 123(18), 2882-2892.

B6.g7 mice reconstituted with BDC2 center dot 5 non-obese diabetic (BDC2 center dot 5NOD) stem cells do not develop autoimmune diabetes
Rajasekaran, N., Wang, N., Hang, Y., Macaubas, C., Rinderknecht, C., & Mellins, E. D. (2013). B6.g7 mice reconstituted with BDC2 center dot 5 non-obese diabetic (BDC2 center dot 5NOD) stem cells do not develop autoimmune diabetes. CLINICAL AND EXPERIMENTAL IMMUNOLOGY, 174(1), 27-37.

Fine mapping of the Bmgr5 quantitative trait locus for allogeneic bone marrow engraftment in mice
Wang, Y., Chen, X., Tsai, S., Thomas, A., Shizuru, J. A., & Cao, T. M. (2013). Fine mapping of the Bmgr5 quantitative trait locus for allogeneic bone marrow engraftment in mice. IMMUNOGENETICS, 65(8), 585-596.

Pathways analysis of differential gene expression induced by engrafting doses of total body irradiation for allogeneic bone marrow transplantation in mice
Chen, X., Wang, Y., Li, Q., Tsai, S., Thomas, A., & Cao, T. M. (2013). Pathways analysis of differential gene expression induced by engrafting doses of total body irradiation for allogeneic bone marrow transplantation in mice. IMMUNOGENETICS, 65(8), 597-607.

Host-derived CD4+T cells attenuate stem cellmediated transfer of autoimmune arthritis in lethally irradiated C57BL/6.g7 mice
Rajasekaran, N., Wang, N., Phi Truong, P., Rinderknecht, C., Macaubas, C., & Mellins, E. D. (2013). Host-derived CD4+T cells attenuate stem cellmediated transfer of autoimmune arthritis in lethally irradiated C57BL/6.g7 mice. ARTHRITIS AND RHEUMATISM, 65(3), 681-692.

The road to purified hematopoietic stem cell transplants is paved with antibodies.
Logan, A. C., Weissman, I. L., & Shizuru, J. A. (2012). The road to purified hematopoietic stem cell transplants is paved with antibodies. Current opinion in immunology, 24(5), 640-648.

Prophylactic rituximab after allogeneic transplantation decreases B-cell alloimmunity with low chronic GVHD incidence
Arai, S., Sahaf, B., Narasimhan, B., Chen, G. L., Jones, C. D., & Miklos, D. B. (2012). Prophylactic rituximab after allogeneic transplantation decreases B-cell alloimmunity with low chronic GVHD incidence. BLOOD, 119(25), 6145-6154.

Tolerance and Withdrawal of Immunosuppressive Drugs in Patients Given Kidney and Hematopoietic Cell Transplants
Scandling, J. D., Busque, S., Dejbakhsh-Jones, S., Benike, C., Sarwal, M., & Strober, S. (2012). Tolerance and Withdrawal of Immunosuppressive Drugs in Patients Given Kidney and Hematopoietic Cell Transplants. AMERICAN JOURNAL OF TRANSPLANTATION, 12(5), 1133-1145.

Co-transplantation of pure blood stem cells with antigen-specific but not bulk T cells augments functional immunity
Mueller, A. Ms., Shashidhar, S., Kuepper, N. J., Kohrt, H. Ek., Florek, M., & Shizuru, J. A. (2012). Co-transplantation of pure blood stem cells with antigen-specific but not bulk T cells augments functional immunity. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 109(15), 5820-5825.

Sirolimus and mycophenolate mofetil as GVHD prophylaxis in myeloablative, matched-related donor hematopoietic cell transplantation
Johnston, L., Florek, M., Armstrong, R., McCune, J. S., Arai, S., & Negrin, R. (2012). Sirolimus and mycophenolate mofetil as GVHD prophylaxis in myeloablative, matched-related donor hematopoietic cell transplantation. BONE MARROW TRANSPLANTATION, 47(4), 581-588.

Long-Term Outcome of Patients with Metastatic Breast Cancer Treated with High-Dose Chemotherapy and Transplantation of Purified Autologous Hematopoietic Stem Cells
Mueller, A. Ms., Kohrt, H. Ek., Cha, S., Laport, G., Klein, J., & Shizuru, J. A. (2012). Long-Term Outcome of Patients with Metastatic Breast Cancer Treated with High-Dose Chemotherapy and Transplantation of Purified Autologous Hematopoietic Stem Cells. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 18(1), 125-133.

Adoptive Immunotherapy with Cytokine-Induced Killer Cells for Patients with Relapsed Hematologic Malignancies after Allogeneic Hematopoietic Cell Transplantation
Laport, G. G., Sheehan, K., Baker, J., Armstrong, R., Wong, R. M., & Negrin, R. S. (2011). Adoptive Immunotherapy with Cytokine-Induced Killer Cells for Patients with Relapsed Hematologic Malignancies after Allogeneic Hematopoietic Cell Transplantation. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 17(11), 1679-1687.

A phase 1 study of imatinib for corticosteroid-dependent/refractory chronic graft-versus-host disease: response does not correlate with anti-PDGFRA antibodies
Chen, G. L., Arai, S., Flowers, M. Ed., Otani, J. M., Qiu, J., & Miklos, D. B. (2011). A phase 1 study of imatinib for corticosteroid-dependent/refractory chronic graft-versus-host disease: response does not correlate with anti-PDGFRA antibodies. BLOOD, 118(15), 4070-4078.

Rapid Reconstitution of Antibody Responses Following Transplantation of Purified Allogeneic Hematopoietic Stem Cells
Linderman, J. A., & Shizuru, J. A. (2011). Rapid Reconstitution of Antibody Responses Following Transplantation of Purified Allogeneic Hematopoietic Stem Cells. JOURNAL OF IMMUNOLOGY, 186(7), 4191-4199.

Long-term outcomes in patients with high-risk myeloid malignancies following matched related donor hematopoietic cell transplantation with myeloablative conditioning of BU, etoposide and CY
Naik, S., Wong, R., Arai, S., Brown, J., Laport, G., & Johnston, L. (2011). Long-term outcomes in patients with high-risk myeloid malignancies following matched related donor hematopoietic cell transplantation with myeloablative conditioning of BU, etoposide and CY. BONE MARROW TRANSPLANTATION, 46(2), 192-199.

Allogeneic T cells impair engraftment and hematopoiesis after stem cell transplantation.
Müller, A. Ms., Linderman, J. A., Florek, M., Miklos, D., & Shizuru, J. A. (2010). Allogeneic T cells impair engraftment and hematopoiesis after stem cell transplantation. Proceedings of the National Academy of Sciences of the United States of America, 107(33), 14721-14726.

Phase I/II Trial of GN-BVC, a Gemcitabine and Vinorelbine-Containing Conditioning Regimen for Autologous Hematopoietic Cell Transplantation in Recurrent and Refractory Hodgkin Lymphoma
Arai, S., Letsinger, R., Wong, R. M., Johnston, L. J., Laport, G. G., & Horning, S. J. (2010). Phase I/II Trial of GN-BVC, a Gemcitabine and Vinorelbine-Containing Conditioning Regimen for Autologous Hematopoietic Cell Transplantation in Recurrent and Refractory Hodgkin Lymphoma. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 16(8), 1145-1154.

Allogeneic haematopoietic cell transplantation after nonmyeloablative conditioning in patients with T-cell and natural killer-cell lymphomas
Shustov, A. R., Gooley, T. A., Sandmaier, B. M., Shizuru, J., Sorror, M. L., & Maloney, D. G. (2010). Allogeneic haematopoietic cell transplantation after nonmyeloablative conditioning in patients with T-cell and natural killer-cell lymphomas. BRITISH JOURNAL OF HAEMATOLOGY, 150(2), 170-178.

Nonmyeloablative Allogeneic Hematopoietic Cell Transplantation in Patients With Acute Myeloid Leukemia
Gyurkocza, B., Storb, R., Storer, B. E., Chauncey, T. R., Lange, T., & Sandmaier, B. M. (2010). Nonmyeloablative Allogeneic Hematopoietic Cell Transplantation in Patients With Acute Myeloid Leukemia. JOURNAL OF CLINICAL ONCOLOGY, 28(17), 2859-2867.

Long-term follow-up of patients with diffuse large B-cell non-Hodgkin's lymphoma receiving purged autografts after induction failure
Benjamin, J. E., Chen, G. L., Cao, T. M., Cao, P. D., Wong, R. M., & Laport, G. G. (2010). Long-term follow-up of patients with diffuse large B-cell non-Hodgkin's lymphoma receiving purged autografts after induction failure. BONE MARROW TRANSPLANTATION, 45(2), 303-309.

The biology of allogeneic hematopoietic cell resistance.
Shizuru, J. A., Bhattacharya, D., & Cavazzana-Calvo, M. (2010). The biology of allogeneic hematopoietic cell resistance. Biology of blood and marrow transplantation , 16(1), S2-7.

Ineffective Vaccination against Solid Tumors Can Be Enhanced by Hematopoietic Cell Transplantation
Filatenkov, A., Mueller, A. Ms., Tseng, W. W.-L., Dejbakhsh-Jones, S., Winer, D., & Strober, S. (2009). Ineffective Vaccination against Solid Tumors Can Be Enhanced by Hematopoietic Cell Transplantation. JOURNAL OF IMMUNOLOGY, 183(11), 7196-7203.

Salvage Allogeneic Hematopoietic Cell Transplantation with Fludarabine and Low-Dose Total Body Irradiation after Rejection of First Allografts
Gyurkocza, B., Cao, T. M., Storb, R. F., Lange, T., Leisenring, W., & Sandmaier, B. M. (2009). Salvage Allogeneic Hematopoietic Cell Transplantation with Fludarabine and Low-Dose Total Body Irradiation after Rejection of First Allografts. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 15(10), 1314-1322.

TLI and ATG conditioning with low risk of graft-versus-host disease retains antitumor reactions after allogeneic hematopoietic cell transplantation from related and unrelated donors
Kohrt, H. E., Turnbull, B. B., Heydari, K., Shizuru, J. A., Laport, G. G., & Lowsky, R. (2009). TLI and ATG conditioning with low risk of graft-versus-host disease retains antitumor reactions after allogeneic hematopoietic cell transplantation from related and unrelated donors. BLOOD, 114(5), 1099-1109.

A chromosome 16 quantitative trait locus regulates allogeneic bone marrow engraftment in nonmyeloablated mice
Cao, T. M., Thomas, A., Wang, Y., Tsai, S., Logronio, K., & Shizuru, J. A. (2009). A chromosome 16 quantitative trait locus regulates allogeneic bone marrow engraftment in nonmyeloablated mice. BLOOD, 114(1), 202-210.

Identification of a Major Susceptibility Locus for Lethal Graft-versus-Host Disease in MHC-Matched Mice
Cao, T. M., Lazzeroni, L. C., Tsai, S., Pang, W. W., Kao, A., & Shizuru, J. A. (2009). Identification of a Major Susceptibility Locus for Lethal Graft-versus-Host Disease in MHC-Matched Mice. JOURNAL OF IMMUNOLOGY, 183(1), 462-469.

Long-term outcome of patients with multiple myeloma after autologous hematopoietic cell transplantation and nonmyeloablative allografting
Rotta, M., Storer, B. E., Sahebi, F., Shizuru, J. A., Bruno, B., & Maloney, D. G. (2009). Long-term outcome of patients with multiple myeloma after autologous hematopoietic cell transplantation and nonmyeloablative allografting. BLOOD, 113(14), 3383-3391.

Purified hematopoietic stem cell allografts reconstitute immunity superior to bone marrow
Tsao, G. J., Allen, J. A., Logronio, K. A., Lazzeroni, L. C., & Shizuru, J. A. (2009). Purified hematopoietic stem cell allografts reconstitute immunity superior to bone marrow. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 106(9), 3288-3293.

The origins of the identification and isolation of hematopoietic stem cells, and their capability to induce donor-specific transplantation tolerance and treat autoimmune diseases
Weissman, I. L., & Shizuru, J. A. (2008). The origins of the identification and isolation of hematopoietic stem cells, and their capability to induce donor-specific transplantation tolerance and treat autoimmune diseases. BLOOD, 112(9), 3543-3553.

Non-myeloablative allogeneic haematopoietic cell transplantation for relapsed diffuse large B-cell lymphoma: a multicentre experience
Rezvani, A. R., Norasetthada, L., Gooley, T., Sorror, M., Bouvier, M. E., & Maloney, D. G. (2008). Non-myeloablative allogeneic haematopoietic cell transplantation for relapsed diffuse large B-cell lymphoma: a multicentre experience. BRITISH JOURNAL OF HAEMATOLOGY, 143(3), 395-403.

Five-Year Follow-Up of Patients With Advanced Chronic Lymphocytic Leukemia Treated With Allogeneic Hematopoietic Cell Transplantation After Nonmyeloablative Conditioning
Sorror, M. L., Storer, B. E., Sandmaier, B. M., Maris, M., Shizuru, J., & Maloney, D. G. (2008). Five-Year Follow-Up of Patients With Advanced Chronic Lymphocytic Leukemia Treated With Allogeneic Hematopoietic Cell Transplantation After Nonmyeloablative Conditioning. JOURNAL OF CLINICAL ONCOLOGY, 26(30), 4912-4920.

Complementing mutations in core binding factor leukemias: from mouse models to clinical applications
Mueller, A., Duque, J., Shizuru, J. A., & Luebbert, M. (2008). Complementing mutations in core binding factor leukemias: from mouse models to clinical applications. ONCOGENE, 27(44), 5759-5773.

Hepatic parenchymal replacement in mice by transplanted allogeneic hepatocytes is facilitated by bone marrow transplantation and mediated by CD4 cells
Streetz, K. L., Doyonnas, R., Grimm, D., Jenkins, D. D., Fuess, S., & Kay, M. A. (2008). Hepatic parenchymal replacement in mice by transplanted allogeneic hepatocytes is facilitated by bone marrow transplantation and mediated by CD4 cells. HEPATOLOGY, 47(2), 706-718.

Brief report: Tolerance and chimerism after renal and hematopoietic-cell transplantation
Scandling, J. D., Busque, S., Dejbakhsh-Jones, S., Benike, C., Millan, M. T., & Strober, S. (2008). Brief report: Tolerance and chimerism after renal and hematopoietic-cell transplantation. NEW ENGLAND JOURNAL OF MEDICINE, 358(4), 362-368.

Nonmyeloablative allogeneic hematopoietic cell transplantation in relapsed, refractory, and transformed indolent non-Hodgkin's lymphoma
Rezvani, A. R., Storer, B., Maris, M., Sorror, M. L., Agura, E., & Maloney, D. G. (2008). Nonmyeloablative allogeneic hematopoietic cell transplantation in relapsed, refractory, and transformed indolent non-Hodgkin's lymphoma. JOURNAL OF CLINICAL ONCOLOGY, 26(2), 211-217.

Factors associated with outcomes in allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning after failed myeloablative hematopoietic cell transplantation
Baron, F., Storb, R., Storer, B. E., Maris, M. B., Niederwieser, D., & Sandmaier, B. M. (2006). Factors associated with outcomes in allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning after failed myeloablative hematopoietic cell transplantation. JOURNAL OF CLINICAL ONCOLOGY, 24(25), 4150-4157.

Nonobese diabetic mice express aspects of both type 1 and type 2 diabetes
Chaparro, R. J., Konigshofer, Y., Beilhack, G. F., Shizuru, J. A., McDevitt, H. O., & Chien, Y.-H. (2006). Nonobese diabetic mice express aspects of both type 1 and type 2 diabetes. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 103(33), 12475-12480.

High-dose carmustine, etoposide, and cyclophosphamide followed by allogeneic hematopoietic cell transplantation for non-Hodgkin lymphoma
Law, L. Y., Horning, S. J., Wong, R. M., Johnston, L. J., Laport, G. G., & Stockerl-Goldstein, K. E. (2006). High-dose carmustine, etoposide, and cyclophosphamide followed by allogeneic hematopoietic cell transplantation for non-Hodgkin lymphoma. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 12(7), 703-711.

Of mice and men
Shizuru, J. A. (2006). Of mice and men. BLOOD, 107(7), 2589-2590.

Treatment for acute myelogenous leukemia by low-dose, total-body, irradiation-based conditioning and hematopoietic cell transplantation from related and unrelated donors
Hegenbart, U., Niederwieser, D., Sandmaier, B. M., Maris, M. B., Shizuru, J. A., & STORB, R. (2006). Treatment for acute myelogenous leukemia by low-dose, total-body, irradiation-based conditioning and hematopoietic cell transplantation from related and unrelated donors. JOURNAL OF CLINICAL ONCOLOGY, 24(3), 444-453.

Protective conditioning for acute graft-versus-host disease
Lowsky, R., Takahashi, T., Liu, Y. P., Dejbakhsh-Jones, S., GRUMET, F. C., & Strober, S. (2005). Protective conditioning for acute graft-versus-host disease. NEW ENGLAND JOURNAL OF MEDICINE, 353(13), 1321-1331.

Hematopoietic cell transplantation from HLA-identical sibling donors after low-dose radiation-based conditioning for treatment of CML
Kerbauy, F. R., STORB, R., Hegenbart, U., Gooley, T., Shizuru, J., & Sandmaier, B. M. (2005). Hematopoietic cell transplantation from HLA-identical sibling donors after low-dose radiation-based conditioning for treatment of CML. LEUKEMIA, 19(6), 990-997.

Prevention of type 1 diabetes with major histocompatibility complex-compatible and nonmarrow ablative hematopoietic stem cell transplants
Beilhack, G. F., Landa, R. R., Masek, M. A., & Shizuru, J. A. (2005). Prevention of type 1 diabetes with major histocompatibility complex-compatible and nonmarrow ablative hematopoietic stem cell transplants. DIABETES, 54(6), 1770-1779.

Prognostic relevance of 'early-onset' graft-versus-host disease following non-myeloablative haematopoietic cell transplantation
Mielcarek, M., Burroughs, L., Leisenring, W., Diaconescu, R., Martin, P. J., & STORB, R. (2005). Prognostic relevance of 'early-onset' graft-versus-host disease following non-myeloablative haematopoietic cell transplantation. BRITISH JOURNAL OF HAEMATOLOGY, 129(3), 381-391.

Engraftment and survival following reduced-intensity allogeneic peripheral blood hematopoietic cell transplantation is affected by CD8(+) T-cell dose
Cao, T. M., Shizuru, J. A., Wong, R. M., Sheehan, K., Laport, G. G., & Lowsky, R. (2005). Engraftment and survival following reduced-intensity allogeneic peripheral blood hematopoietic cell transplantation is affected by CD8(+) T-cell dose. BLOOD, 105(6), 2300-2306.

CD34, CD49 and CD8 cell doses do not influence engraftment, graft-versus-host disease, or survival following myeloablative human leukocyte antigen-identical peripheral blood allografting for hematologic malignancies
Cao, T. M., Wong, R. M., Sheehan, K., Laport, G. G., Stockerl-Goldstein, K. E., & Lowsky, R. (2005). CD34, CD49 and CD8 cell doses do not influence engraftment, graft-versus-host disease, or survival following myeloablative human leukocyte antigen-identical peripheral blood allografting for hematologic malignancies. EXPERIMENTAL HEMATOLOGY, 33(3), 279-285.

Rapamycin (sirolimus) for treatment of chronic graft-versus-host disease
Johnston, L. J., Brown, J., Shizuru, J. A., Stockerl-Goldstein, K. E., Stuart, M. J., & Chao, N. J. (2005). Rapamycin (sirolimus) for treatment of chronic graft-versus-host disease. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 11(1), 47-55.

Hematopoietic stem and progenitor cells: Clinical and preclinical regeneration of the hematolymphoid system
Shizuru, J. A., Negrin, R. S., & Weissman, I. L. (2005). Hematopoietic stem and progenitor cells: Clinical and preclinical regeneration of the hematolymphoid system. ANNUAL REVIEW OF MEDICINE, 56, 509-538.

Cytokines and cytotoxic pathways in engraftment resistance to purified allogeneic hematopoietic stem cells
Scheffold, C., Scheffold, J. C., Cao, T. M., Gworek, J., & Shizuru, J. A. (2005). Cytokines and cytotoxic pathways in engraftment resistance to purified allogeneic hematopoietic stem cells. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 11(1), 1-12.

Approaches to transplantation tolerance in humans
Strober, S., Lowsky, R. J., Shizuru, J. A., Scandling, J. D., & Millan, M. T. (2004). Approaches to transplantation tolerance in humans. TRANSPLANTATION, 77(6), 932-936.

Rituximab as adjuvant to high-dose therapy and autologous hematopoietic cell transplantation for aggressive non-Hodgkin lymphoma
Horwitz, S. M., Negrin, R. S., Blume, K. G., Breslin, S., Stuart, M. J., & Horning, S. J. (2004). Rituximab as adjuvant to high-dose therapy and autologous hematopoietic cell transplantation for aggressive non-Hodgkin lymphoma. BLOOD, 103(3), 777-783.

Variable hematopoietic graft rejection and graft-versus-host disease in MHC-matched strains of mice
Cao, T. M., Lo, B., Ranheim, E. A., GRUMET, F. C., & Shizuru, J. A. (2003). Variable hematopoietic graft rejection and graft-versus-host disease in MHC-matched strains of mice. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 100(20), 11571-11576.

Common lymphoid progenitors rapidly engraft and protect against lethal murine cytomegalovirus infection after hematopoietic stem cell transplantation
Arber, C., Bitmansour, A., Sparer, T. E., Higgins, J. P., Mocarski, E. S., & Brown, J. My. (2003). Common lymphoid progenitors rapidly engraft and protect against lethal murine cytomegalovirus infection after hematopoietic stem cell transplantation. BLOOD, 102(2), 421-428.

Reconstitution of NK cell receptor repertoire following HLA-matched hematopoietic cell transplantation
Shilling, H. G., McQueen, K. L., Cheng, N. W., Shizuru, J. A., Negrin, R. S., & Parham, P. (2003). Reconstitution of NK cell receptor repertoire following HLA-matched hematopoietic cell transplantation. BLOOD, 101(9), 3730-3740.

Biology of hematopoietic stem cells and progenitors: Implications for clinical application
Kondo, M., Wagers, A. J., Manz, M. G., Prohaska, S. S., Scherer, D. C., & Weissman, I. L. (2003). Biology of hematopoietic stem cells and progenitors: Implications for clinical application. ANNUAL REVIEW OF IMMUNOLOGY, 21, 759-806.

Purified allogeneic hematopoietic stem cell transplantation blocks diabetes pathogenesis in NOD mice
Beilhack, G. F., Scheffold, Y. C., Weissman, I. L., TAYLOR, C., Jerabek, L., & Shizuru, J. A. (2003). Purified allogeneic hematopoietic stem cell transplantation blocks diabetes pathogenesis in NOD mice. DIABETES, 52(1), 59-68.

Immune tolerance to combined organ and bone marrow transplants after fractionated lymphoid irradiation involves regulatory NK T cells and clonal deletion
Higuchi, M., Zeng, D. F., Shizuru, J., Gworek, J., Dejbakhsh-Jones, S., & Strober, S. (2002). Immune tolerance to combined organ and bone marrow transplants after fractionated lymphoid irradiation involves regulatory NK T cells and clonal deletion. JOURNAL OF IMMUNOLOGY, 169(10), 5564-5570.

Mixed chimerism and immunosuppressive drug withdrawal after HLA-mismatched kidney and hematopoietic progenitor transplantation
Millan, T. Lt., Shizuru, J. A., Hoffmann, P., Dejbakhsh-Jones, S., Scandling, J. D., & Strober, S. (2002). Mixed chimerism and immunosuppressive drug withdrawal after HLA-mismatched kidney and hematopoietic progenitor transplantation. TRANSPLANTATION, 73(9), 1386-1391.

Rapid establishment of dendritic cell chimerism in allogeneic hematopoietic cell transplant recipients
Auffermann-Gretzinger, S., Lossos, I. S., Vayntrub, T. A., Leong, W., GRUMET, F. C., & Shizuru, J. A. (2002). Rapid establishment of dendritic cell chimerism in allogeneic hematopoietic cell transplant recipients. BLOOD, 99(4), 1442-1448.

Immunity to infections following hematopoietic cell transplantation
Brown, J. M., Weissman, I. L., & Shizuru, J. A. (2001). Immunity to infections following hematopoietic cell transplantation. CURRENT OPINION IN IMMUNOLOGY, 13(4), 451-457.

Nonmyeloablative hematopoietic stem cell transplantation: Transplantation for the 21(st) century
Maris, M., Woolfrey, A., McSweeney, P. A., Sandmaier, B. M., Nash, R. A., & STORB, R. (2001). Nonmyeloablative hematopoietic stem cell transplantation: Transplantation for the 21(st) century. FRONTIERS IN BIOSCIENCE-LANDMARK, 6, G13-G16.

Non-myeloablative hematopoietic stem cell transplantation
Maris, M., Sandmaier, B. M., Maloney, D. G., McSweeney, P. A., Woolfrey, A., & Storb, R. (2001). Non-myeloablative hematopoietic stem cell transplantation. TRANSFUSION CLINIQUE ET BIOLOGIQUE, 8(3), 231-234.

Expansion of cytolytic CD8(+) natural killer T cells with limited capacity for graft-versus-host disease induction due to interferon gamma production
Baker, J., Verneris, M. R., Ito, M., Shizuru, J. A., & Negrin, R. S. (2001). Expansion of cytolytic CD8(+) natural killer T cells with limited capacity for graft-versus-host disease induction due to interferon gamma production. BLOOD, 97(10), 2923-2931.

Toward regenerative medicine
Lagasse, E., Shizuru, J. A., Uchida, N., Tsukamoto, A., & Weissman, I. L. (2001). Toward regenerative medicine. IMMUNITY, 14(4), 425-436.

Engineering hematopoietic grafts: Purified allogeneic hematopoietic stem cells plus expanded CD8(+) NK-T cells in the treatment of lymphoma
Verneris, M. R., Ito, M., Baker, E., Arshi, A., Negrin, R. S., & Shizuru, J. A. (2001). Engineering hematopoietic grafts: Purified allogeneic hematopoietic stem cells plus expanded CD8(+) NK-T cells in the treatment of lymphoma. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 7(10), 532-542.

Efficacy and toxicity of a CCNU-containing high-dose chemotherapy regimen followed by autologous hematopoietic cell transplantation in relapsed or refractory Hodgkin's disease
Stuart, M. J., Chao, N. S., Horning, S. J., Wong, R. M., Negrin, R. S., & Goldstein, S. (2001). Efficacy and toxicity of a CCNU-containing high-dose chemotherapy regimen followed by autologous hematopoietic cell transplantation in relapsed or refractory Hodgkin's disease. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 7(10), 552-560.

High-dose therapy and autologous hematopoietic-cell transplantation for follicular lymphoma beyond first remission: The Stanford University experience
Cao, T. M., Horning, S. F., Negrin, R. S., Hu, W. W., Johnston, L. F., & Stockerl-Goldstein, K. (2001). High-dose therapy and autologous hematopoietic-cell transplantation for follicular lymphoma beyond first remission: The Stanford University experience. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 7(5), 294-301.

Allogeneic hematopoietic stem cell transplantation: From the nuclear age into the twenty-first century
Storb, R., McSweeney, P. A., Sandmaier, B. M., Nash, R. A., Georges, G., & Niederwieser, D. (2000). Allogeneic hematopoietic stem cell transplantation: From the nuclear age into the twenty-first century. TRANSPLANTATION PROCEEDINGS, 32(7), 2548-2549.

Purified hematopoietic stem cell grafts induce tolerance to alloantigens and can mediate positive and negative T cell selection
Shizuru, J. A., Weissman, I. L., Kernoff, R., Masek, M., & Scheffold, Y. C. (2000). Purified hematopoietic stem cell grafts induce tolerance to alloantigens and can mediate positive and negative T cell selection. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 97(17), 9555-9560.

Effect of oral glutamine supplementation during bone marrow transplantation
Dickson, T. Mc., Wong, R. M., Negrin, R. S., Shizuru, J. A., JOHNSTON, L. J., & Stockerl-Goldstein, K. E. (2000). Effect of oral glutamine supplementation during bone marrow transplantation. JOURNAL OF PARENTERAL AND ENTERAL NUTRITION, 24(2), 61-66.

Four-cycle high-dose therapy with hematopoietic support for metastatic breast cancer: No improvement in outcomes compared with single-course high-dose therapy
Hu, W. W., Negrin, R. S., Stockerl-Goldstein, K., JOHNSTON, L. J., Shizuru, J. A., & Blume, K. G. (2000). Four-cycle high-dose therapy with hematopoietic support for metastatic breast cancer: No improvement in outcomes compared with single-course high-dose therapy. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 6(1), 58-69.

Pulmonary toxicity syndrome in breast cancer patients undergoing BCNU-containing high-dose chemotherapy and autologous hematopoietic cell transplantation
Cao, T. M., Negrin, R. S., Stockerl-Goldstein, K. E., JOHNSTON, L. J., Shizuru, J. A., & Hu, W. W. (2000). Pulmonary toxicity syndrome in breast cancer patients undergoing BCNU-containing high-dose chemotherapy and autologous hematopoietic cell transplantation. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 6(4), 387-394.

Immune reconstitution
Weissman, I. L., & Shizuru, J. A. (1999). Immune reconstitution. NEW ENGLAND JOURNAL OF MEDICINE, 341(16), 1227-1229.

Lymphoid development from stem cells and the common lymphocyte progenitors
Akashi, K., Kondo, M., Cheshier, S., Shizuru, J., Gandy, K., & Weissman, I. L. (1999). Lymphoid development from stem cells and the common lymphocyte progenitors. COLD SPRING HARBOR SYMPOSIA ON QUANTITATIVE BIOLOGY, 64, 1-12.

Impact of admission body weight and chemotherapy dose adjustment on the outcome of autologous bone marrow transplantation.
Dickson, T. M., Kusnierz-Glaz, C. R., Blume, K. G., Negrin, R. S., Hu, W. W., & Stockerl-Goldstein, K. E. (1999). Impact of admission body weight and chemotherapy dose adjustment on the outcome of autologous bone marrow transplantation. Biology of blood and marrow transplantation , 5(5), 299-305.

Graft-vs.-lymphoma effect in an allogeneic hematopoietic stem cell transplantation model.
Ito, M., & Shizuru, J. A. (1999). Graft-vs.-lymphoma effect in an allogeneic hematopoietic stem cell transplantation model. Biology of blood and marrow transplantation , 5(6), 357-368.

From stem cells to lymphocytes: Biology and transplantation
Aguila, H. L., Akashi, K., Domen, J., Gandy, K. L., Lagasse, E., & Weissman, I. L. (1997). From stem cells to lymphocytes: Biology and transplantation. IMMUNOLOGICAL REVIEWS, 157, 13-40.

Transplantation of purified hematopoietic stem cells: requirements for overcoming the barriers of allogeneic engraftment.
Shizuru, J. A., Jerabek, L., Edwards, C. T., & Weissman, I. L. (1996). Transplantation of purified hematopoietic stem cells: requirements for overcoming the barriers of allogeneic engraftment. Biology of blood and marrow transplantation , 2(1), 3-14.

Anti-CD4 antibodies in diabetes.
Shizuru, J. A., & Fathman, C. G. (1993). Anti-CD4 antibodies in diabetes. Immunology series, 59, 237-252.

THE USE OF GRANZYME A AS A MARKER OF HEART-TRANSPLANT REJECTION IN CYCLOSPORINE OR ANTI-CD4 MONOCLONAL ANTIBODY-TREATED RATS
CHEN, R. H., IVENS, K. W., Alpert, S., Billingham, M. E., Fathman, C. G., & Griffiths, G. M. (1993). THE USE OF GRANZYME A AS A MARKER OF HEART-TRANSPLANT REJECTION IN CYCLOSPORINE OR ANTI-CD4 MONOCLONAL ANTIBODY-TREATED RATS. TRANSPLANTATION, 55(1), 146-153.

GENETIC-CONTROL OF DIABETES-MELLITUS
Weatherall, D., Sarvetnick, N., & Shizuru, J. A. (1992). GENETIC-CONTROL OF DIABETES-MELLITUS. DIABETOLOGIA, 35, S1-S7.

ANTI-CD4 MONOCLONAL-ANTIBODIES IN THERAPY - CREATION OF NONCLASSICAL TOLERANCE IN THE ADULT
Shizuru, J. A., Alters, S. E., & Fathman, C. G. (1992). ANTI-CD4 MONOCLONAL-ANTIBODIES IN THERAPY - CREATION OF NONCLASSICAL TOLERANCE IN THE ADULT. IMMUNOLOGICAL REVIEWS, 129, 105-130.

ANTI-CD8 ABROGATES EFFECT OF ANTI-CD4-MEDIATED ISLET ALLOGRAFT SURVIVAL IN RAT MODEL
SEYDEL, K., Shizuru, J., Grossman, D., Wu, A., Alters, S., & Fathman, C. G. (1991). ANTI-CD8 ABROGATES EFFECT OF ANTI-CD4-MEDIATED ISLET ALLOGRAFT SURVIVAL IN RAT MODEL. DIABETES, 40(11), 1430-1434.

GENETIC DISSECTION OF T-CELL RECEPTOR-V-BETA GENE REQUIREMENTS FOR SPONTANEOUS MURINE DIABETES
Shizuru, J. A., TAYLOREDWARDS, C., Livingstone, A., & Fathman, C. G. (1991). GENETIC DISSECTION OF T-CELL RECEPTOR-V-BETA GENE REQUIREMENTS FOR SPONTANEOUS MURINE DIABETES. JOURNAL OF EXPERIMENTAL MEDICINE, 174(3), 633-638.

TRANSGENIC MICE FOR THE STUDY OF DIABETES-MELLITUS
Shizuru, J. A., & Sarvetnick, N. (1991). TRANSGENIC MICE FOR THE STUDY OF DIABETES-MELLITUS. TRENDS IN ENDOCRINOLOGY AND METABOLISM, 2(3), 97-104.

GENETIC-ANALYSIS OF DIABETES IN THE NONOBESE DIABETIC MOUSE .1. MHC AND T-CELL RECEPTOR BETA-GENE EXPRESSION
Livingstone, A., Edwards, C. T., Shizuru, J. A., & Fathman, C. G. (1991). GENETIC-ANALYSIS OF DIABETES IN THE NONOBESE DIABETIC MOUSE .1. MHC AND T-CELL RECEPTOR BETA-GENE EXPRESSION. JOURNAL OF IMMUNOLOGY, 146(2), 529-534.

INDUCTION OF DONOR-SPECIFIC UNRESPONSIVENESS TO CARDIAC ALLOGRAFTS IN RATS BY PRETRANSPLANT ANTI-CD4 MONOCLONAL-ANTIBODY THERAPY
Shizuru, J. A., Seydel, K. B., Flavin, T. F., Wu, A. P., Kong, C. C., & Fathman, C. G. (1990). INDUCTION OF DONOR-SPECIFIC UNRESPONSIVENESS TO CARDIAC ALLOGRAFTS IN RATS BY PRETRANSPLANT ANTI-CD4 MONOCLONAL-ANTIBODY THERAPY. TRANSPLANTATION, 50(3), 366-373.

LOSS OF PANCREATIC-ISLET TOLERANCE INDUCED BY BETA-CELL EXPRESSION OF INTERFERON-GAMMA
Sarvetnick, N., Shizuru, J., Liggitt, D., Martin, L., McIntyre, B., & Stewart, T. (1990). LOSS OF PANCREATIC-ISLET TOLERANCE INDUCED BY BETA-CELL EXPRESSION OF INTERFERON-GAMMA. NATURE, 346(6287), 844-847.

THE MOLECULAR-BASIS OF ANTIGEN-SPECIFIC RECOGNITION BY LYMPHOCYTES-T
Danska, J. S., Livingstone, A. M., Shizuru, J., & Fathman, C. G. (1990). THE MOLECULAR-BASIS OF ANTIGEN-SPECIFIC RECOGNITION BY LYMPHOCYTES-T. DEFENSE MOLECULES, 121, 241-254.

CARDIAC ALLOGRAFT PROLONGATION IN MICE TREATED WITH COMBINED POSTTRANSPLANTATION TOTAL-LYMPHOID IRRADIATION AND ANTI-L3T4 ANTIBODY THERAPY
TRAGER, D. K., Banks, B. A., Rosenbaum, G. E., HOLM, B. I., Shizuru, J. A., & Fathman, C. G. (1989). CARDIAC ALLOGRAFT PROLONGATION IN MICE TREATED WITH COMBINED POSTTRANSPLANTATION TOTAL-LYMPHOID IRRADIATION AND ANTI-L3T4 ANTIBODY THERAPY. TRANSPLANTATION, 47(4), 587-591.

INFLAMMATORY DESTRUCTION OF PANCREATIC BETA-CELLS IN GAMMA-INTERFERON TRANSGENIC MICE
Sarvetnick, N., Shizuru, J., Liggitt, D., & Stewart, T. (1989). INFLAMMATORY DESTRUCTION OF PANCREATIC BETA-CELLS IN GAMMA-INTERFERON TRANSGENIC MICE. IMMUNOLOGICAL RECOGNITION, PTS 1 AND 2, 54, 837-842.

USE OF ANTI-L3T4 AND ANTI-IA TREATMENTS FOR PROLONGATION OF XENOGENEIC ISLET TRANSPLANTS
Kaufman, D. S., Kong, C. S., Shizuru, J. A., Gregory, A. K., & Fathman, C. G. (1988). USE OF ANTI-L3T4 AND ANTI-IA TREATMENTS FOR PROLONGATION OF XENOGENEIC ISLET TRANSPLANTS. TRANSPLANTATION, 46(2), 210-215.

IMMUNOTHERAPY OF THE NONOBESE DIABETIC MOUSE - TREATMENT WITH AN ANTIBODY TO T-HELPER LYMPHOCYTES
Shizuru, J. A., TAYLOREDWARDS, C., Banks, B. A., Gregory, A. K., & Fathman, C. G. (1988). IMMUNOTHERAPY OF THE NONOBESE DIABETIC MOUSE - TREATMENT WITH AN ANTIBODY TO T-HELPER LYMPHOCYTES. SCIENCE, 240(4852), 659-662.

ISLET ALLOGRAFT SURVIVAL AFTER A SINGLE COURSE OF TREATMENT OF RECIPIENT WITH ANTIBODY TO L3T4
Shizuru, J. A., Gregory, A. K., CHAO, C. Tb., & Fathman, C. G. (1987). ISLET ALLOGRAFT SURVIVAL AFTER A SINGLE COURSE OF TREATMENT OF RECIPIENT WITH ANTIBODY TO L3T4. SCIENCE, 237(4812), 278-280.

INHIBITION OF RAT MIXED LYMPHOCYTE PANCREATIC-ISLET CULTURES WITH ANTI-IA IMMUNOTOXIN
Shizuru, J. A., Ramakrishnan, S., Hunt, T., Merrell, R. C., & Fathman, C. G. (1986). INHIBITION OF RAT MIXED LYMPHOCYTE PANCREATIC-ISLET CULTURES WITH ANTI-IA IMMUNOTOXIN. TRANSPLANTATION, 42(6), 660-666.

STRUCTURE, FUNCTION, AND IMMUNE PROPERTIES OF REASSOCIATED ISLET CELLS
Shizuru, J., Trager, D., & Merrell, R. C. (1985). STRUCTURE, FUNCTION, AND IMMUNE PROPERTIES OF REASSOCIATED ISLET CELLS. DIABETES, 34(9), 898-903.